Edward Whitehorne

With more than three decades of experience both as an active member of the angel investment community and in research and development, Edward Whitehorne brings a diverse blend of financial acumen, investment experience and technical expertise to the FHI Clinical Board of Directors.

An experienced investor with in-depth expertise in informatics, research and development, Mr. Whitehorne joined the FHI 360 Board of Directors in 2000, served as Vice Chair and became Chair in 2014, before retiring from the FHI Board in 2018. Mr. Whitehorne also previously served as Chair of FHI 360’s Executive Committee. He was a founder of Clinical Research International and a founding member of the Atlantis Group and TriState Investment Groups II, III and IV and served on their executive committees.

From 1999 to 2013, Mr. Whitehorne was a member of the Board of Directors of Novella Clinical, Inc., a leader in oncology and medical device clinical trials. In 2013, he led the sale of Novella to Quintiles, Inc. He also serves as a trustee of the FHI Foundation and chairs its investment committee.